Project Grant R01HL185414
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Trustees of Boston University a Project Grant of $166,752 (Award Date: September 1, 2025; Completion Date: August 31, 2027) under the Cardiovascular Diseases Research program (CFDA 93.837) to advance understanding of lung branching morphogenesis through synthetic biology approaches. The research deliverables will include fundamental discoveries regarding the signaling mechanisms—specifically...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) awarded Massachusetts General Hospital a Project Grant of $1,579,554 on September 10, 2025, for research concluding June 30, 2030. The award funds an integrated genomic and functional research initiative to decipher the mechanisms underlying chronic obstructive pulmonary disease (COPD) and asthma—two of the most common and costly chronic respiratory...
- Federal Project Grant Award Summary Brigham & Women's Hospital Inc. received a $1.41 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 1, 2025, with completion targeted for May 31, 2029. The award funds research to characterize lung interstitial neutrophils (LINs)—a specialized immune cell subset with enhanced bactericidal capacity. The project investigates the origin,...
- Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Washington University a Project Grant of $1.9M (awarded June 15, 2026; completion February 28, 2028) under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct fundamental mechanistic research addressing chronic muco-obstructive lung disease. The research identifies and corrects a pathological reprogramming pathway in basal epithelial stem cells (basal-ESCs) that drives persistent airway...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $156,168 to the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center for research exploring the role of the Hedgehog pathway-primary cilia axis in human lung alveolarization and disease under the Cardiovascular Diseases Research program (CFDA 93.837). The two-year project, initiated August 1, 2025 and concluding July 31, 2027, investigates how hedgehog signaling regulates alveolar...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $490,500 Project Grant to Boston University Medical Campus (Trustees of Boston University) beginning September 1, 2025, with a completion date of May 31, 2029, under the Cardiovascular Diseases Research program (CFDA 93.837). The research investigates novel mechanistic insights into inflammation and organ injury resulting from dysregulated host defense in bacterial pneumonia and sepsis....
- Federal Project Grant Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Boston University Medical Campus (Trustees of Boston University) a $1,471,655 Project Grant beginning September 1, 2025, and extending through May 31, 2030, under the Cardiovascular Diseases Research program (CFDA 93.837). The project, "Quantifying Uncertainty to Inform Time-Limited Trials of Invasive Mechanical Ventilation," delivers evidence-based guidance to optimize the use of time-limited...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Feinstein Institutes for Medical Research a Project Grant of $586,866 under the Cardiovascular Diseases Research program (CFDA 93.837) on May 15, 2026, with a completion date of February 28, 2030. This award funds research investigating the critical role of B-1A cells, an immunoregulatory B cell subset, in mitigating acute lung injury (ALI) and acute respiratory distress...
- Federal Project Grant Award Summary Baylor College of Medicine received a $1.60M project grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 15, 2026, with completion scheduled for April 30, 2028. The grant funds basic research investigating the role of the let-7 microRNA/EZH2/BACH1 double negative feedback loop in alveolar cell-induced interstitial lung disease (ILD). The research addresses a critical...
- Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant of $770,247 to Massachusetts General Hospital (The General Hospital Corporation) on July 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds mechanistic research investigating the cellular and molecular basis of airway metaplastic responses, with anticipated completion by February 28, 2030. The research will establish the propensity of anatomically regionalized...
Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $712,630 to Trustees of Boston University, with an award date of August 1, 2026, and completion deadline of April 30, 2030, under the Cardiovascular Diseases Research program (CFDA 93.837). The project, titled "Functional Heterogeneity of Alveoli and the Early Response to Airborne Agents," will deliver fundamental research outputs advancing understanding of lung physiology and immune response mechanisms. The work utilizes an innovative intravital imaging platform called the Crystal Ribcage to enable real-time, high-resolution visualization of intact, ventilating lung tissue, producing the first single-particle resolution imaging of aerosol deposition within functional alveoli and discovery of a conserved mosaic pattern of anatomical organization. The funded research will generate three primary deliverables: (1) detailed anatomical and physiological mapping of alveolar mosaicism, including spatial relationships between functionally distinct alveolar types and the first alveolus-level oxygen pressure mapping across multiple species including humans; (2) transcriptomic and spatial transcriptomics data characterizing gene expression differences in alveolar type 2 cells and macrophages from distinct alveolar compartments, alongside developmental evidence regarding preferential alveologenesis; and (3) mechanistic findings regarding how injurious aerosols differentially activate immune and injury responses based on alveolar location. These research outputs are expected to establish the biological significance of previously undescribed lung architecture and inform future therapeutic strategies for airborne agent exposure and respiratory disease.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $712.6k | 7/15/26 |